Drug Profile
CNTO 5
Alternative Names: CNTO-5Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MorphoSys
- Developer Janssen Biotech
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation in Germany (Parenteral)
- 10 Jan 2013 CNTO 5 is in phase I development in Inflammation
- 22 Jun 2011 Centocor Ortho Biotech is now called Janssen Biotech